Recently, a new PROTAC degrader targeting SMARCA2 and SMARCA4, called AU-15330, was found to have great preferential cytotoxicity at low concentrations in AR/FOXA1-driven prostate cancer [170]. This evidence concerns the gene SMARCA4 and prostate carcinoma.